Haemonetics HAE
NYSE HAE
$101.14 -2.02 (-1.96%)
As of: Sep 10, 2026 · 3:59 PM EDT

Haemonetics (HAE) Gains from Investment Securities (2013 - 2022)

Haemonetics (HAE) posted Gains from Investment Securities of -$504000.0 for Q3 2022, down 366.67% on a QoQ basis from $189000.0 in Q2 2022, and down 105.16% year-over-year from $9.8 million in Q3 2021.

Analysis

Haemonetics (HAE) Gains from Investment Securities (2013 - 2022) Analysis & Trends

Haemonetics has reported Gains from Investment Securities for 5 years, with the latest figure at -$504000.0 in Q3 2022.

  • On a quarterly basis, Gains from Investment Securities fell 105.16% year-over-year to -$504000.0 in Q3 2022; TTM through Apr 2023 was -$504000.0, a 104.82% decrease from a year earlier, with the FY2023 full-year figure at -$504000.0, down 104.82% from the prior year.
  • Gains from Investment Securities was -$504000.0 for Q3 2022 at Haemonetics, down from $189000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $9.8 million in Q3 2021, with the low at -$504000.0 in Q3 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 179.79 Bn 174.18 Bn 7.27 Bn
2 Intuitive Surgical 127.69 Bn 122.47 Bn 1.96 Bn
3 Medtronic 117.23 Bn 108.41 Bn 6.34 Bn
4 Stryker 103.55 Bn 100.07 Bn 4.50 Bn
5 Boston Scientific 63.24 Bn 62.70 Bn 3.85 Bn
6 Edwards Lifesciences 49.97 Bn 45.72 Bn 1.35 Bn
7 Alcon 32.83 Bn 31.37 Bn 1.68 Bn
8 Dexcom 32.30 Bn 30.35 Bn 830.00 Mn
9 Steris 20.73 Bn 20.25 Bn 684.20 Mn
10 Haemonetics 4.60 Bn 4.37 Bn 202.80 Mn
Historic Data

Historic Data

Download Data
DateValue
Jul 2, 2022 -504,000.00
Apr 2, 2022 189,000.00
Jan 1, 2022 927,000.00
Oct 2, 2021 -429,000.00
Jul 3, 2021 9.77 Mn
Dec 26, 2015 -4.90 Mn
Sep 26, 2015 88,000.00
Jun 27, 2015 83,000.00
Mar 28, 2015 -3.62 Mn
Dec 27, 2014 246,000.00
Sep 27, 2014 235,000.00
Jun 28, 2014 224,000.00
Mar 29, 2014 -1.14 Mn
Dec 28, 2013 872,000.00
Sep 28, 2013 189,000.00
Jun 29, 2013 121,000.00